Skip to content
★ Sign in to follow
AD

Asaf Danziger

Executive
Chairman & CEO
NovoCure Ltd
Total declarations
156
Company
1
▲ Purchases (4 ops.)
€593k
▼ Sales (101 ops.)
€175.7M

Latest filing published 01 Jul 2026 for NovoCure Ltd.

Filing timeline

BuySale
Asaf Danziger

Insider track record

Disclosed buys
4
Disclosed sells
101
T+90 hit rate
100%
T+90 mean return
+10.3%

Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.

Signal history

Asaf Danziger: trading record in brief

Asaf Danziger, listed as chief executive, appears in our data through filings on Novocure Ltd shares, published by SEC (Form 4). The record holds 156 filings, for trades running from 3 March 2016 to 30 June 2026.

On the open market, the record shows 4 purchases worth €593k and 101 sales worth €175.7M. Sales outweigh purchases by €175.1M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 20 share grants and 31 option exercises.

A typical purchase (the median) is worth €115k. Of 4 purchases, 1 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The latest filing, published on 1 July 2026, reports a share grant in Novocure Ltd. The latest purchase dates back some time: it was published 1,805 days ago, on 29 November 2021. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.

Companies and markets linked to Asaf Danziger

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations10 total
  • ◆
    DirectorExecutivesNovoCure Ltd
    0SEC
    268 sharesOrdinary SharesSEC:0001654435-26-000003:0
  • ◆
    DirectorExecutivesNovoCure Ltd
    12,603 USD13SEC
    833 shares@ US$15.131.5% of flowOrdinary SharesSEC:0001562180-25-005187:0
  • ◆
    DirectorExecutivesNovoCure Ltd
    6,076 USD22SEC
    412 shares@ US$14.7480.6% of flowOrdinary SharesSEC:0001562180-25-000065:0
  • ◆
    Chief Executive OfficerExecutivesNovoCure Ltd
    15,165 USD33SEC
    1,239 shares@ US$12.241.3% of flowOrdinary SharesSEC:0001562180-24-006041:0
  • ◆
    Chief Executive OfficerExecutivesNovoCure Ltd
    12,948 USD33SEC
    367 shares@ US$35.281.1% of flowOrdinary SharesSEC:0001562180-23-005755:0
  • ◇
    Chief Executive OfficerExecutivesNovoCure Ltd
    286,500 USD36SEC
    25,000 shares@ US$11.4625.6% of flowOrdinary SharesSEC:0001645113-23-000007:0
  • ◆
    Chief Executive OfficerExecutivesNovoCure Ltd
    16,305 USD37SEC
    276 shares@ US$59.0751.5% of flowOrdinary SharesSEC:0001645113-22-000062:0
  • ◆
    Chief Executive OfficerExecutivesNovoCure Ltd
    1,978 USD28SEC
    31 shares@ US$63.8180.3% of flowOrdinary SharesSEC:0001645113-22-000004:0
  • ▲
    Chief Executive OfficerExecutivesNovoCure Ltd
    396,133 USD31SEC
    3,870 shares@ US$102.3650.7% of flowOrdinary SharesSEC:0001645113-21-000116:0
    Canonical exit: 24 Feb 2022 (T+90)
  • ◆
    Chief Executive OfficerExecutivesNovoCure Ltd
    16,180 USD22SEC
    118 shares@ US$137.1222.0% of flowOrdinary SharesSEC:0001645113-21-000084:0

10 of 10 declarations